Novel Progesterone Antagonists Reducing Glucocorticoid Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current progesterone antagonists, while effective in treating certain forms of cancer, face limitations due to glucocorticoid receptor antagonism and the need for more potent and selective antiprogestagenic activity.
Innovation Solution
Development of novel progesterone antagonists with specific structural formulas, such as those described in formulas (I) and (II), which exhibit enhanced antiprogestagenic activity with reduced glucocorticoid antagonism, allowing for targeted therapy in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Mifepristone is used as a progesterone antagonist, then potent progesterone antagonism is achieved, but glucocorticoid receptor antagonism occurs which limits long-term clinical use
Solution Approach 1:
The patent applies local quality by introducing specific substituents at particular positions on the steroid nucleus to modulate receptor selectivity. For example, replacing the 11β-phenyl group of Mifepristone with other aromatic or heteroaromatic groups at this specific location creates compounds that maintain progesterone receptor binding while reducing glucocorticoid receptor interaction, thus achieving localized optimization of pharmacological properties
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types (aryl, heteroaryl, cycloalkyl groups), their positions, and stereochemistry at positions 11β and other locations on the steroid core. These parameter modifications alter the molecular properties to achieve dissociation between progesterone and glucocorticoid receptor affinities, transforming the compound's selectivity profile
2Object-generated harmful factors
If existing progesterone antagonists like Onapristone, ORG-33628, PROELLEX, or Lonaprisan are used, then improved dissociation from glucocorticoid antagonism is achieved, but further enhancement of antiprogestagenic activity is needed
Solution Approach 1:
The patent continues the parameter optimization strategy by exploring diverse substituent classes including pyridyl, pyrimidinyl, triazolyl heteroaromatic groups, and various cycloalkyl substituents. These systematic parameter variations allow fine-tuning of the balance between progesterone receptor antagonism potency and glucocorticoid receptor selectivity, seeking compounds with enhanced therapeutic indices
Solution Approach 2:
The patent creates composite molecular structures by combining the steroid core with various aromatic and heteroaromatic substituents, effectively creating hybrid molecules that integrate properties of different chemical classes. This composite approach allows the molecule to achieve complex receptor interaction profiles with high progesterone antagonism and low glucocorticoid activity
Data Source
AI summary
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.